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Variants in Filamin C (FLNC) gene may cause either cardiomyopathies or different myopathies. We describe 
a family affected by a distal myopathy with autosomal dominant inheritance. The onset of the disease was in 
the third decade with gait impairment due to distal leg weakness. Subsequently, the disease progressed with 
an involvement of proximal lower limbs and hand muscles. Muscle biopsy, performed in one 
subject,identified relevant myofibrillar abnormalities.   
We performed a target gene panel testing for myofibrillar myopathies by NGS approach which identified a 
novel mutation in exon 3 of FLNC gene (c.A664G:p.M222V), within the N-terminal actin-binding (ABD) 
domain. This variant has been identified in all affected members of the family, thus supporting its pathogenic 
role. Differently from previously identified variants, our family showed a predominant leg involvement and 
myofibrillar aggregates, thus further expanding the spectrum of Filamin C related myopathies.  
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Title: A novel mutation in the N-terminal acting-binding domain of Filamin C protein causing a distal 
myofibrillar myopathy. 
 
Dear Editor,  
Introduction:   
Filamins are 3 actin-crosslinking proteins, including: A, B and C. They share a common structure: a N-
terminal ABD consisting of two calponin homology (CH) domains, followed by a semiflexible rod of 24 
immunoglobulin-like repeats and a C-terminal dimerization domain [1]. The gene FLNC is located in 7q32-
q35 chromosome and codifies for Filamin C, the muscle specific isoform expressed in the cardiac and 
skeletal muscles [2]. Filamin C localizes in the Z-disc, here interacting with different proteins including 
myotilin [1] and extends in the sarcolemma where it connects to both the transmembrane receptor β1-integrin 
[3] and the dystrophin-glycoprotein complex [4]. Through these connections, Filamin C stabilizes the actin 
filament networks and links it to cell membranes[5]. Mutations in FLNC cause progressive myopathies or 
different cardiomyopathies [6]. Different types of Filamin C related muscle phenotypes have been described 
according to the mutation domain [5]. Mutations in rod domain tend to cause a proximal myopathy with 
onset in fourth-to-sixth decade and with typical myofibrillar features with frequent involvement of the 
cardiac and respiratory muscles [7]. Conversely, mutations in the actin-binding domain (ABD) of FLNC are 
responsible for another phenotype, initially characterized by weakness and wasting of distal muscles, 
especially intrinsic hand muscles, manifesting in the third decade of life and a later involvement of posterior 
calf muscles, in this case muscle biopsy usually showings non-specific myopathic abnormalities without 
myofibrillar derangement [8]. Further, FLNC ABD domain can also cause a late onset myopathy 
characterized by predominant limb-girdle weakness, starting in the fifth decade and later spreading to distal 
and respiratory muscles, resembling the phenotype of mutations in the rod domain of FLNC. [9]. 
 
Case Report:  
Two brothers come to our attention when they were 51 and 46 years old respectively. Motor milestones had 
been unremarkable. Both patients reported difficulties in walking, running and frequent nocturnal leg cramps 















gradually extended to the proximal muscles of the lower limbs and involved the hands after 10 years. The 
disease course slowly worsened from walking with single support by the beginning of the fifth decade to the 
loss of ambulation ten years after. The youngest brother reported also frequent extra-systoles, without any 
respiratory involvement. In the family history, the mother presented difficulties in walking and a maternal 
cousin,  presented a similar clinical course. In both patients CK levels remained within the normal range and, 
at the beginning of the disease, nerve conduction studies showed reduced compound muscle action potentials 
(cMAP) amplitudes in lower limb nerves, with no significant abnormalities at the electromyography (EMG), 
suggesting a possible axonal motor neuropathy. Later on, when performed at the age of 51, EMG showed 
myopathic features in the older brother. He underwent a quadriceps femoris muscle biopsy which showed 
variations in muscle fiber size, with several atrophic fibers, some centralized nuclei and a type 1 fiber 
predominance. Relevant myofibrillar abnormalities, including impairment of myofibrillar alignment, 
presence of massive cytoplasmic aggregated and non-rimmed vacuoles were evident on Gomori trichrome 
and NADH stains (Fig.1, A, B, C). Lobulated or ring fibers were also recognized. Immunofluorescence 
showed myotilin accumulations within the fibers and a positive desmin reaction in a rim surrounding the 
vacuoles or the deposits (Fig.1, D-E). A musculoskeletal MRI revealed a complete fatty substitution of lower 
limb muscles (Fig.1 G). 
We performed a target gene panel testing for myofibrillar myopathies by Next Generation Sequencing 
(NGS) approach, designed with Agilent’s HaloPlex technology loaded on Illumina MiSeq sequencer. We 
identified in the two brothers a novel heterozygous mutation in exon 3 of FLNC gene (c.664A>G:p.M222V, 
NM_001458), within the N-terminal ABD domain, never reported in any public population database. No 
other variants were identified in any of the 35 genes analyzed with this panel (supplementary material). 
Moreover, this variant was confirmed by direct sequencing in an affected cousin and her mother, both living 
in a different Italian area, while it was excluded in two healthy cousins (Fig. 1, F). The mother of our two 
patients died before any genetic assessment could be performed. Further, the variant was not found in 
controls (Exome Sequencing Project, 1000 Genomes Project, or Genome Aggregation Consortium). 
The mutation falls in a highly conserved region (Fig.1, H) of a well-established functional domain and 
multiple lines of computational evidence support a deleterious effect on the gene or gene product (SIFT, 















performed. In particular, the primary sequence of wild type human Filamin C (Uniprot code Q14315) was 
downloaded.  The three-dimensional structure of the protein human Filamin A, with Protein Data Bank 
archive code 3HOP, was used as template and mutated on residues T215E and M222V (T223 and M229) 
using the Mutagenesis wizard implemented in PyMOl (https://pymol.org) (Fig.1, I). By in silico analysis, the 
variant M222V does not significantly alter protein properties in that region, since a non-polar residue as 
methionine is substituted by a smaller, again non polar, residue. However, this model has limitations since 
human Filamin A, in this region, has a 87% homology with Filamin C and the cristal structure of ABD 
domain of Filamin C is not available. 
  
Discussion:  
Myofibrillar myopathies represent a heterogeneous group of inherited muscle disorders sharing common 
pathologic features, with protein aggregates and myofibrillar disorganization and with a frequent 
involvement of distal muscles. In the past, the diagnostic approach was a gene by gene analysis, often 
requiring a long time to reach a molecular diagnosis which was possible in a restricted number of cases. 
Conversely, the use of NGS is increasing the diagnostic yield of molecular diagnoses and contributes to 
increase the complexity of genotype/phenotype correlations. 
In this paper we describe a different phenotype for a mutation falling in the ABD domain of FLNC, thus 
expanding the clinical spectrum of FLNC-related myopathies. Most previously identified mutations in ABD 
domain cause distal myopathies without myofibrillar features and with thenar and intrinsic hand muscle 
wasting as clinical presentation [1]. Differently, our family showed a predominant early anterior leg 
involvement and myofibrillar alterations at muscle biopsy resembling dense granulofilamentous protein 
aggregates described in other myofibrillar myopathies caused by mutation in the dimerization domain of 
Filamin C. [10]. Moreover, although the age of onset was similar to other distal forms (third decade), the 
course of the disease was more severe in our family, leading to the loss of ambulation by 60 years old and a 
complete lower limb muscle atrophy as demonstrated by a muscle MRI (Fig. 1, G). Since literature 
highlights a pulmonary and/or cardiac involvement for different mutations in FLNC gene [6,7], we 















youngest brother without evident structural cardiac abnormalities. Therefore, this mutation is not correlated 
to a cardiac phenotype. 
Despite a robust computational evidence supporting a deleterious effect of this novel Filamin-C variant, the 
protein modelling did not confirm a significant impairment of the protein, however the study is based on the 
cristal structure of Filamin-A, which shares a partial homology with Filamin C. 
Moreover,  the segregation of the variant in all affected members together with its lack from controls (Exome 
Sequencing Project, 1000 Genomes Project, or Genome Aggregation Consortium), all support a pathogenic 
role of our mutation.  
We can speculate that this mutation could cause a mislocation of the filamin protein with decreased nuclear 
localization and formation of cytoplasmatic protein aggregates through a gain of function as already 
described in different ABD mutation of FLNC causing distal myopathies [1]. However, the precise link to 
myofibrillar abnormalities is unknown and functional studies will be necessary to investigate this hypothesis.  
Our data support the use of NGS to reach a molecular diagnosis in neuromuscular diseases and confirm that 
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Figure Legends:  
Figure 1: A-B: NADH staining (magnification 20 X in A and B, 40x in C) shows lobulated fibres (circled) 
and areas of devoid activity, sometimes core-like, suggesting a disarrangement of the myofibrillar network. 
Additionally several large rotund inclusion of granulofilamentous material are present, resembling ring or 
targetoid fibres. C: Gomori Trichrome staining (TG, magnification 60x oil) shows rimmed and non-rimmed 
vacuoles and several scattered atrophic fibres or nuclear clumps. D-E: Immunofluorescence with antibodies 
against Myotilin 1:500 (Thermofisher PA5-29059) and Desmin 1:200 (Abcam ab15200) evidenced that the 
inclusions of the ring fibers are composed by a central cluster rich of myotilin (E) surrounded by a ring of 
desmin positive material (E). F: Family tree: III, 1 and III, 2 the two brothers. II,3 and III, 3 the affected aunt 
and affected cousin in which the mutation was confirmed. III, 4 and III, 5 two healthy cousins in which the 
mutation was excluded. G: musculoskeletal MRI of lower limb muscles showed a complete fatty substitution 
of lower limb muscles, several decades after the onset. H: Multiple alignments of Filamin C in different 
orthologous show the high conservation of the residue p. M222 in the second calponin domain. I: The three-
dimensional structure of mutant protein implemented in PyMOl (https://pymol.org ) 
 

















Novel mutation in FLNC gene (c.A664G:p.M222V), within the N-terminal ABD domain. 
A predominant  distal leg involvement and severe clinical course in FLNC mutation.  
Myofibrillar abnormalities and target fibres in distal myopathy due to FLNC mutation.  
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